Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2024 Q2 | Jul 1, 2024 | Protean Select | 0.0% | 10.6% | ACAST.ST, AMBEA.ST, CAMURUS.ST, CARG.HE, CARL-B.CO, CINT.ST, DEVYSER.ST, ITAB.ST, KEMIRA.HE, METSB.HE, METSO.HE, NETEL.ST, NORVA.ST, PROACT.ST, RAY-B.ST, REJL.ST, TIETO.HE, TRUE-B.ST, TRYG.CO, VALMT.HE | Absolute return, AI Bubble, Hedge Fund, Nordics, risk management, small caps | Manager views AI as a classic boom-bust cycle, comparing it to historical manias. Chat-GPT usage is already declining and trillion-dollar AI investments will take years to generate returns above cost of capital. The fund is short names that have risen on misplaced AI enthusiasm. | TRUE.ST NOR.ST CAMX.ST METSB.HE |
View |
| 2024 Q2 | Jul 1, 2024 | Protean Funds | 0.0% | 24.3% | ACAST.ST, AMBEA.ST, AUTO.OL, CAMX.ST, CGCBV.HE, CINT.ST, DEVYSER.ST, FASAD.ST, ITAB.ST, KEMIRA.HE, KOJAMO.HE, METSB.HE, NETEL.ST, NORVA.ST, PROACT.ST, RAY.ST, REJL.ST, TIE1V.HE, VAIAS.HE, VALMT.HE | AI, inflation, Nordics, risk management, small cap, value | Manager views AI as a classic boom-bust cycle, comparing it to historical manias. Chat-GPT usage is already declining and trillion-dollar AI investments may take years to generate returns above cost of capital. | TRUE.ST NORVA.ST CAMX.ST METSB.HE |
View |
| 2024 Q1 | Jun 18, 2024 | Protean Funds | 0.0% | 24.3% | ACAST.ST, AMBE.ST, BICO.ST, BOULE.ST, CARG.HE, CINT.ST, DEVYSER.ST, EMBEL.ST, EVO.ST, FORTUM.HE, ITAB.ST, LINDEX.ST, NIBE.ST, NOLA.ST, PROACT.ST, RAY.ST, TIETO.ST, VALMT.HE | active management, Nordics, Outperformance, Quality, small caps, value | The fund focuses exclusively on Nordic small-cap opportunities with roughly 50 names in the portfolio. The manager emphasizes that small-cap funds provide a bigger opportunity set than larger competitors, though acknowledges that growing assets reduce nimbleness. The fund will cap at 4bn SEK to maintain its small-cap focus. | NIBE.ST EVO.ST BOULE.ST EMBEL.ST ITAB.ST ACAST.ST |
View |
| 2026 Q1 | Apr 1, 2026 | Protean Small Cap | - | - | BALD-B.ST, CINT.ST, DEVYSER.ST, NIBE-B.ST, RUSTA.ST, VERTI.ST | active management, Energy Transition, Geopolitical, Heat Pumps, Nordics, small caps, volatility | VERT.ST VIMIAN.ST DEVYSER.ST CINT.ST NIBE.ST |
View | |
| 2026 Q1 | Apr 1, 2026 | Protean Select | - | - | BALD-B.ST, BOL.ST, BTS-B.ST, CINT.ST, DEVYSER.ST, ELUX-B.ST, GETI-B.ST, LUMI.TO, NIBE-B.ST, NYFO.ST, RUSTA.ST, SMART.OL, VERTI.ST, VIMIAN.ST, VOLV-B.ST | Energy Transition, Geopolitical Risk, Heat Pumps, Hedge Fund, Nordics, small caps, volatility | DEVYSER.ST VIMIAN.ST CINT.ST NIBE.ST |
View | |
| 2024 Q4 | Jan 7, 2025 | Protean Select | - | 11.0% | ACAST.ST, AMBEA.ST, BAVA.CO, CARGOTEC.HE, CINT.ST, DEVYSER.ST, EMBRAC-B.ST, EVO.ST, GETI-B.ST, HEXA-B.ST, HM-B.ST, HUMBLE.ST, INTEA.ST, ITAB.ST, NVO, PROACT.ST, RAYSEARCH.ST, STEN-A.ST, TRYG.CO | Hedge Fund, Long/Short, Nordics, Pharmaceuticals, real estate, small caps | Significant focus on pharmaceutical investments including Novo Nordisk's Cagrisema trial results and Bavarian Nordic's vaccine franchise. The manager discusses pharma stocks trading on 5+ year growth potential and development timelines. | INTEA.ST NVO BAVA.CO |
View |
| 2024 Q4 | Jan 7, 2025 | Protean Small Cap | - | 24.0% | ACAST.ST, AMBEA.ST, BAVA.CO, CGCBV.HE, CINT.ST, DEVYSER.ST, EMBRAC-B.ST, EVO.ST, GETI-B.ST, HEXA-B.ST, HM-B.ST, HUMBLE.ST, INTEA.ST, ITAB.ST, NOVO-B.CO, PROACT.ST, RAYSEARCH.ST, STORA-A.ST, TRYG.CO | growth, Nordics, real estate, small caps, Vaccines, value | The fund focuses on Nordic small caps as its core strategy, believing they offer superior return potential despite higher volatility. The manager emphasizes that small caps are their home turf where they benefit from being a small fund with the ability to be nimble and versatile. | INTEA.ST BAVA.CO |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | Fund Letters | Protean Select | Cint | Software - Application | Internet Software & Services | Bull | New York Stock Exchange | Equity, growth, Market Research, Media Measurement, SaaS, Sweden, technology platform, turnaround | View Pitch |
| Apr 28, 2026 | Fund Letters | Fairlight Alpha Fund | Intellego Technologies | Materials | Specialty Chemicals | Bull | Nasdaq First North Growth Market | Early stage, healthcare, industrial applications, Photochromic Technology, specialty chemicals, Sweden, technology, UV Protection | View Pitch |
| Apr 9, 2026 | Fund Letters | Protean Small Cap | Cint Group AB | Software - Application | Internet Software & Services | Bull | New York Stock Exchange | AI impact, growth, high-risk, Market Research, Media Measurement, Sequential Improvement, technology platform, turnaround | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||